Today, the President & CEO of Loxo Oncology (NASDAQ: LOXO), Joshua Bilenker, sold shares of LOXO for $7.51M.
In addition to Joshua Bilenker, 4 other LOXO executives reported Sell trades in the last month.
See today’s analyst top recommended stocks >>
Based on Loxo Oncology’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $38.43 million and GAAP net loss of $3.56 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $24.53 million. Currently, Loxo Oncology has an average volume of 703.4K. The Company has a Price to Book ratio of 13.9644.
Based on 9 analyst ratings, the analyst consensus is Strong Buy with an average price target of $218.67, reflecting a -16.1% downside.
The insider sentiment on Loxo Oncology has been negative according to 61 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT.
